Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Genmab
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Verastem, Inc.
Hoffmann-La Roche
AstraZeneca
Pfizer
Regeneron Pharmaceuticals
Thomas Jefferson University
Providence Health & Services
AstraZeneca
Washington University School of Medicine
Genentech, Inc.
TJ Biopharma Co., Ltd.
Swiss Cancer Institute
Maia Biotechnology
Bristol-Myers Squibb
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
University Health Network, Toronto
Intergroupe Francophone de Cancerologie Thoracique
Hoffmann-La Roche
University of Southern California
Bristol-Myers Squibb
Weill Medical College of Cornell University
Incyte Corporation
Swiss Cancer Institute
Trishula Therapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Hospital Sultanah Bahiyah
Eli Lilly and Company
AstraZeneca
NGM Biopharmaceuticals, Inc
SWOG Cancer Research Network
Hummingbird Bioscience
Fox Chase Cancer Center
Qianfoshan Hospital
EpicentRx, Inc.
Spanish Lung Cancer Group
National Cancer Institute (NCI)
EMD Serono
Phanes Therapeutics